<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="955">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148715</url>
  </required_header>
  <id_info>
    <org_study_id>MP-31-2020-3348</org_study_id>
    <nct_id>NCT05148715</nct_id>
  </id_info>
  <brief_title>CINERGY Pilot Trial</brief_title>
  <acronym>CINERGY</acronym>
  <official_title>Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)-Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that preconditioning neurologically deceased organ donors with&#xD;
      the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival&#xD;
      without causing harm. Organ donors will be randomized to receive either 0.02 mg/kg ideal body&#xD;
      weight (IBW) of tacrolimus single infusion or placebo before organ recovery. All&#xD;
      corresponding recipients are enrolled and data is collected up to 7 days post-transplant to&#xD;
      determine graft function and at 1 year to collect outcomes of vital status,&#xD;
      re-transplantation and dialysis. The CINERGY Pilot Trial assesses feasibility for the main&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Organ donation saves lives, and improves quality of life for thousands of people.&#xD;
      But organ donation falls short of expectations for some patients who suffer early graft loss.&#xD;
      During organ donation surgery, the supply of blood with oxygen and nutrients is suspended.&#xD;
      When restored during transplant surgery, a cascade of inflammation perturbs the newly&#xD;
      transplanted organ -causing ischemia-reperfusion injury. When severe, it can hinder&#xD;
      transplant function in the early post-operative period, lead to profound critical illness,&#xD;
      increase the risks of transplant rejection and chronic disease, and reduce the transplant&#xD;
      lifespan. Administration of tacrolimus, a calcineurin inhibitor, to neurologically deceased&#xD;
      donors may reduce ischemia-reperfusion injury in transplant recipients.&#xD;
&#xD;
      Objectives: The CINERGY Pilot Trial will test the feasibility of comparing tacrolimus to&#xD;
      placebo for the prevention of delayed graft function in kidney recipients and establish the&#xD;
      foundation for a large, multi-centre randomized controlled trial (RCT).&#xD;
&#xD;
      Methods: 90 neurologically deceased kidney donors will be randomized to either tacrolimus&#xD;
      (0.02 mg/kg) or the corresponding placebo 4-8 hours before organ recovery. To be included in&#xD;
      the CINERGY Pilot RCT, donors will need to meet inclusion criteria. All corresponding&#xD;
      recipients are enrolled and their data is collected in the first 7 days and at 12 months&#xD;
      after transplantation.&#xD;
&#xD;
      Outcomes: Feasibility: Donor accrual rate and consent rate of organ recipients. Safety: acute&#xD;
      kidney injury, hyperkalemia and anaphylaxis in donors and recipients. Clinical: graft&#xD;
      function within 7 days in all recipients, vital status, re-transplantation and need for&#xD;
      dialysis at 12 months.&#xD;
&#xD;
      Relevance: This pilot study will inform the feasibility and design of a larger trial.&#xD;
      Moreover, the CINERGY Pilot RCT will pave the way for future trials linking organ donation&#xD;
      and transplantation across Canada.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ donor accrual rates</measure>
    <time_frame>6 to 12 months after the beginning of the trial</time_frame>
    <description>One primary objective of this pilot study is to determine if a national multi-centre placebo randomized controlled trial (RCT) will be feasible with respect to: organ donor accrual.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recipient consent rate</measure>
    <time_frame>6 to 12 months after the beginning of the trial</time_frame>
    <description>Another primary objective of this pilot study is to determine if a national multi-centre placebo controlled RCT will be feasible with respect to the consent rates of organ recipients. Recipient consent rates will be assessed during analysis, analyzing the rate and reasons for non-enrolment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between two methods for obtaining survival status</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>We will compare 2 methods (Hospital records, Canadian Institute for Health Information) for obtaining recipient survival at 12 months post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexpected adverse events</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>In donors and recipients, unexpected adverse events as identified by clinical staff will be reported and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of donors with acute kidney injury (AKI)</measure>
    <time_frame>Within 4 hours after the end of the study drug infusion</time_frame>
    <description>AKI defined as defined as Kidney disease: Improving global outcome (KDIGO) stage II (or more): serum creatinine ≥ 2.0 times baseline OR a urine output &lt;0.5mL/kg/h for ≥12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of donors with hyperkalemia</measure>
    <time_frame>Within 4 hours after the end of the study drug infusion</time_frame>
    <description>Hyperkalemia defined as a potassium level &gt; 5 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of donors hypertension during tacrolimus infusion</measure>
    <time_frame>Within 4 hours after the initiation of study drug infusion</time_frame>
    <description>Hypertension (systolic blood pressure ≥ 160 mmHg or mean arterial pressure ≥ 90 mmHg for &gt; 15 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of donors with cardiac arrhythmia associated with tacrolimus infusion</measure>
    <time_frame>Within 4 hours after the initiation of study drug infusion</time_frame>
    <description>Cardiac arrhythmias defined as new onset of atrial fibrillation or flutter, ventricular tachycardia or fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of donors with anaphylaxis</measure>
    <time_frame>Within 4 hours after the initiation of study drug infusion</time_frame>
    <description>Anaphylaxis defined as per The American Academy of Allergy, Asthma and Immunology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of recipients with acute kidney injury</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>AKI defined as defined as KDIGO stage II or more: serum creatinine ≥ 2.0 times baseline OR a urine output &lt;0.5mL/kg/h for ≥12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of recipients with hyperkalemia</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>Hyperkalemia defined as a potassium level &gt; 5 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of recipients with anaphylaxis</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>Anaphylaxis defined as per The American Academy of Allergy, Asthma and Immunology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient serum tacrolimus levels</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>Clinical research staff will abstract routine serum tacrolimus levels (when measured) from hospital records over the first 7 days, along with local thresholds for toxic level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of liver recipients with early graft function</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>At least ≥ 1 of the following criteria: Bilirubin ≥ 10 mg/dL , International normalized ratio (INR) ≥ 1.6 AST or ALT level &gt; 2000 IU/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>Need to be re-transplanted or to be on the re-transplant list.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient survival</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>Recipient death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipients requiring dialysis</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>Recipient requirement for dialysis at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of lungs recipients with severe primary graft dysfunction</measure>
    <time_frame>Within 3 days post transplant</time_frame>
    <description>PaO2/FiO2 ratio &lt;200 and diffuse infiltration/pulmonary edema on chest radiograph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of kidney recipients with delayed graft function</measure>
    <time_frame>Within 7 days post transplant</time_frame>
    <description>Requirement of ≥ 1 hemodialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of heart recipients with severe primary graft dysfunction</measure>
    <time_frame>Within 1 days post transplant</time_frame>
    <description>Dependence on mechanical support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pancreas recipients with delayed graft function</measure>
    <time_frame>At hospital discharge, an average of 7 days</time_frame>
    <description>Requirement of ≥1 exogenous insulin at hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Organ Transplant Failure or Rejection</condition>
  <condition>Brain Death</condition>
  <condition>Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus 0.02 mg/kg ideal body weight 4-8 hours before organ recovery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride 4-8 hours before organ recovery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Neurologically deceased donors who meet the inclusion and exclusion criteria will be&#xD;
        eligible for participating in this study along with the correlating organ recipients who&#xD;
        meet inclusion criteria.&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age;&#xD;
&#xD;
          -  Neurologically deceased;&#xD;
&#xD;
          -  Consent for deceased organ donation;&#xD;
&#xD;
          -  All organ recipients have been identified;&#xD;
&#xD;
          -  ≥ 1 kidney allocated to a recipient.&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to tacrolimus or polyoxyl 60 hydrogenated castor oil;&#xD;
&#xD;
          -  One or more organs allocated to a non-participating transplant program;&#xD;
&#xD;
          -  Unlikely access to study drug (e.g., due to supply issues, or pharmacist&#xD;
             availability);&#xD;
&#xD;
          -  One or more organ recipients has not agreed to receive an organ from a donor&#xD;
             participating in the study;&#xD;
&#xD;
          -  One or more organs are allocated to a recipient under the age of 18;&#xD;
&#xD;
          -  A transplant physician has judged that donor tacrolimus will be unsuitable for an&#xD;
             intended recipient.&#xD;
&#xD;
        Recipient Inclusion Criteria&#xD;
&#xD;
          -  Organ/Transplant graft originated from a donor enrolled in this study.&#xD;
&#xD;
        No exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérick D'Aragon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maureen Meade</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Selzner</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Breau</last_name>
    <phone>9055259140</phone>
    <phone_ext>22114</phone_ext>
    <email>breaur@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Maureen Meade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gordon Boyd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khaled Shamseddin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marat Slessarev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Shane English</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Karen Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Markus Selzner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L'Institut de Cardiologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Anique Ducharme</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Caroline Lamarche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Michaël Chassé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre universitaire de santé McGill (CUSM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Prosanto Chaudhury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Québec- Université Laval</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Alexis Turgeon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de recherche CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <investigator>
      <last_name>Frédérick D'Aragon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>organ donation and transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

